Skip to main contentSkip to navigationSkip to search
SEK  %

Enzymatica conducts a directed issue totalling SEK 19 million

Regulatory information

The biotech company, Enzymatica, successfully completed a directed issue yesterday, raising around SEK 19 million before deducting issue expenses, under the authority of a resolution of the annual general meeting held on 6 May. The capital raised will be used primarily in the launch of the new treatment for the common cold, ColdZyme® Mouth Spray, on the Swedish market, and to finance the Company’s on-going research and product development work.

At the annual general meeting held on 6 May, the Board was authorised, at its own discretion, to issue a maximum of 2,000,000 new shares with or without pre-emption right, with the aim of raising capital to finance the Company’s future expansion. The Board subsequently resolved to conduct a directed issue of 890,000 shares, corresponding to SEK 19 million before issue expenses. Both institutional and private investors subscribed for the shares at a price of SEK 21 per share, through a standard book-building process. The aim of the issue and the reason for waiving pre-emption rights was to finance the Company’s future expansion while broadening the Company’s long-term strategic shareholder base.

The new issue involves a dilution of 5 percent in the total number of shares after the issue. The subscription price was determined through negotiation with potential investors, and is considered to be at market price. As a result of the issue, the number of Enzymatica shares has increased by 890,000, from 17,879,151 to 18,769,151, and the share capital has risen by SEK 35,600, from SEK 715,000 to a new total of SEK 750,600.

Erik Penser Bankaktiebolag acted as financial advisor and bookrunner for the new issue.

”We are delighted that we succeeded in attracting new institutional and private investors. The capital raised will enable us to implement a comprehensive market launch of ColdZyme in Sweden this autumn, and will provide considerable resources for our research and product development work,” says Michael Edelborg Christensen.

For more information, please contact:
Michael Edelborg Christensen, CEO, Enzymatica AB (publ), +46 (0)768-14 41 66,